Metadoxine ER: Ph III MEASURE data

Top-line data from the double-blind, U.S. and Israeli Phase III MEASURE trial in 283 adult patients with ADHD showed that once-daily 1,400 mg oral metadoxine ER missed the primary endpoint of improvin...